All Stories

  1. Pharmacological Treatment of Alcohol use Disorder in Patients with Psychotic Disorders: A Systematic Review

    Article • Current Neuropharmacology, May 2024, Bentham Science Publishers

    Associate professor Mikkel Højlund, Angelina Isabella Mellentin

  2. Neonatal and maternal outcomes with elective cesarean section compared to induction of labor in twin pregnancies: A prospective cohort study

    Article • European Journal of Obstetrics & Gynecology and Reproductive Biology, July 2023, Elsevier

    Associate professor Mikkel Højlund

  3. The future of child and adolescent clinical psychopharmacology: A systematic review of phase 2, 3, or 4 randomized controlled trials of pharmacologic agents without regulatory approval or for unapproved indications

    Article • Neuroscience & Biobehavioral Reviews, June 2023, Elsevier

    Associate professor Mikkel Højlund

  4. Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review

    Article • World Psychiatry, January 2023, Wiley

    Associate professor Mikkel Højlund

  5. The future of psychopharmacology: a critical appraisal of ongoing phase 2/3 trials, and of some current trends aiming to de‐risk trial programmes of novel agents

    Article • World Psychiatry, January 2023, Wiley

    Associate professor Mikkel Højlund

  6. Response to: The use of low-dose quetiapine does not necessarily increase the risk of major adverse cardiovascular events

    Article • Acta Neuropsychiatrica, January 2023, Cambridge University Press

    Associate professor Mikkel Højlund

  7. Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia

    Article • Expert Opinion on Investigational Drugs, December 2022, Taylor & Francis

    Associate professor Mikkel Højlund

  8. Use of benzodiazepines and benzodiazepine‐related drugs in the Nordic countries between 2000 and 2020

    Article • Basic & Clinical Pharmacology & Toxicology, November 2022, Wiley

    Associate professor Mikkel Højlund

  9. Impact of low‐dose quetiapine‐use on glycosylated hemoglobin, triglyceride and cholesterol levels

    Article • Acta Psychiatrica Scandinavica, November 2022, Wiley

    Associate professor Mikkel Højlund

  10. Use of low‐dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator‐controlled cohort study

    Article • World Psychiatry, September 2022, Wiley

    Associate professor Mikkel Højlund

  11. Free‐of‐charge dispensing of antipsychotics for schizophrenia in Denmark: Impact on the nationwide prescription registry and redemption of somatic medications

    Article • Basic & Clinical Pharmacology & Toxicology, August 2022, Wiley

    Associate professor Mikkel Højlund

  12. Psychopharmacological treatment patterns prior to a schizophrenia diagnosis: A Danish nationwide study

    Article • Schizophrenia Research, August 2022, Elsevier

    Associate professor Mikkel Højlund

  13. Lithium and the risk of chronic kidney disease: A population‐based case–control study

    Article • Basic & Clinical Pharmacology & Toxicology, June 2022, Wiley

    Associate professor Mikkel Højlund

  14. Hospitalization time is associated with weight gain in forensic mental health patients

    Article • European Psychiatry, June 2022, Royal College of Psychiatrists

    Associate professor Mikkel Højlund

  15. Who prescribes quetiapine in Denmark?

    Article • British Journal of Clinical Pharmacology, May 2022, Wiley

    Associate professor Mikkel Højlund

  16. Risk of adverse events after covid-19 in Danish children and adolescents and effectiveness of BNT162b2 in adolescents: cohort study

    Article • BMJ, April 2022, BMJ

    Associate professor Mikkel Højlund

  17. Hospitalisation time is associated with weight gain in forensic mental health patients with schizophrenia or bipolar disorder

    Article • Nordic Journal of Psychiatry, April 2022, Taylor & Francis

    Associate professor Mikkel Højlund

  18. Development and Validation of a Nordic Multimorbidity Index Based on Hospital Diagnoses and Filled Prescriptions

    Article • Clinical Epidemiology, April 2022, Taylor & Francis

    Associate professor Mikkel Højlund

  19. Use of chlorprothixene and the risk of diabetes and major adverse cardiovascular events: A nationwide cohort study

    Article • Basic & Clinical Pharmacology & Toxicology, February 2022, Wiley

    Associate professor Mikkel Højlund

  20. Limitations in Research on Maintenance Treatment for Individuals With Schizophrenia

    Article • JAMA Psychiatry, January 2022, American Medical Association (AMA)

    Associate professor Mikkel Højlund

  21. RE : Gout and sodium‐glucose cotransporter‐2 inhibitors

    Article • Pharmacoepidemiology and Drug Safety, November 2021, Wiley

    Associate professor Mikkel Højlund

  22. Diagnostic accuracy of focused deep venous, lung, cardiac and multiorgan ultrasound in suspected pulmonary embolism: a systematic review and meta-analysis

    Article • Thorax, September 2021, BMJ

    Associate professor Mikkel Højlund

  23. Lung ultrasound to phenotype chronic lung allograft dysfunction in lung transplant recipients. A prospective observational study

    Article • September 2021, European Respiratory Society (ERS)

    Jesper Rømhild Davidsen, Associate professor Mikkel Højlund

  24. Diagnostic accuracy of focused deep venous, lung, cardiac, and multiorgan ultrasound in suspected pulmonary embolism: a systematic review and meta-analysis

    Article • September 2021, European Respiratory Society (ERS)

    Associate professor Mikkel Højlund

  25. Withdrawal-associated relapse is a potential source of bias – Authors' reply

    Article • The Lancet Psychiatry, September 2021, Elsevier

    Associate professor Mikkel Højlund

  26. Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials

    Article • The Lancet Psychiatry, June 2021, Elsevier

    Associate professor Mikkel Højlund

  27. Sodium‐glucose cotransporter‐2 inhibitors and the risk of gout: A Danish population based cohort study and symmetry analysis

    Article • Pharmacoepidemiology and Drug Safety, May 2021, Wiley

    Associate professor Mikkel Højlund

  28. Association of Low-Dose Quetiapine and Diabetes

    Article • JAMA Network Open, May 2021, American Medical Association (AMA)

    Associate professor Mikkel Højlund

  29. How to Estimate QT Interval in Patients With Left or Right Bundle Branch Block

    Article • Journal of Clinical Psychopharmacology, April 2021, Wolters Kluwer Health

    Associate professor Mikkel Højlund

  30. Lung Ultrasound to Phenotype Chronic Lung Allograft Dysfunction in Lung Transplant Recipients. A Prospective Observational Study

    Article • Journal of Clinical Medicine, March 2021, MDPI AG

    Associate professor Mikkel Højlund

  31. Use of antipsychotics in Denmark 1997–2018: a nation-wide drug utilisation study with focus on off-label use and associated diagnoses

    Article • Epidemiology and Psychiatric Sciences, January 2021, Cambridge University Press

    Associate professor Mikkel Højlund

  32. Second-generation antipsychotics and the risk of chronic kidney disease: a population-based case-control study

    Article • BMJ Open, August 2020, BMJ

    Associate professor Mikkel Højlund

  33. Trends in utilization and dosing of antipsychotic drugs in Scandinavia: Comparison of 2006 and 2016

    Article • British Journal of Clinical Pharmacology, May 2019, Wiley

    Associate professor Mikkel Højlund

  34. Effect of a 30-Month Health-Promoting Program on the Prevalence of Cardiovascular Risk Factors in Patients With First Episode Schizophrenia

    Article • American Journal of Therapeutics, January 2019, Wolters Kluwer Health

    Associate professor Mikkel Højlund

  35. Obstructive hydrocephalus caused by colloid cyst presenting as a schizophrenia-like psychosis

    Article • BMJ Case Reports, June 2018, BMJ

    Associate professor Mikkel Højlund

  36. Does the use of medication go up, when the use of restraint go down?

    Article • International Journal of Social Psychiatry, February 2018, SAGE Publications

    Associate professor Mikkel Højlund

  37. Differences in Antipsychotic Prescriptions Between Centers in Young Outpatients With Schizophrenia

    Article • Journal of Clinical Psychopharmacology, December 2017, Wolters Kluwer Health

    Associate professor Mikkel Højlund

  38. Does life-style intervention lower the need for antipsychotics in ypung people with schizophrenia?

    Article • Nordic Journal of Psychiatry, August 2017, Taylor & Francis

    Associate professor Mikkel Højlund

  39. QTc interval in patients with schizophrenia receiving antipsychotic treatment as monotherapy or polypharmacy

    Article • CNS Spectrums, June 2017, Cambridge University Press

    Associate professor Mikkel Højlund

  40. Does the Use of Psychotropic Medication go up During Focused Efforts to Bring Coercion and Restraint Down?

    Article • European Psychiatry, April 2017, Cambridge University Press

    Associate professor Mikkel Højlund

  41. Decrease in antipsychotic and other psychotropic medication during 30 months of lifestyle intervention among outpatients with schizophrenia

    Article • European Psychiatry, April 2017, Cambridge University Press

    Associate professor Mikkel Højlund

  42. Life-threatening effects of antipsychotic drugs (1st edition)

    Article • Nordic Journal of Psychiatry, March 2017, Taylor & Francis

    Associate professor Mikkel Højlund